Web Stats Provided By Google Analytics

Saturday, March 10, 2018

Sanofi: Praluent (alirocumab) significantly reduced risk of...

... safety profile of Praluent was consistent with previous trials and no new safety issues were observed Paris and Tarrytown, N.Y. - March 10, 2018 - Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the ODYSSEY OUTCOMES trial met its ...

No comments:

Post a Comment

Popular Tarrytown Roundup Posts